Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cryo Cell International (CCEL) EPS (Weighted Average and Diluted) (2016 - 2025)

Cryo Cell International (CCEL) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with -$0.46 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 109.09% to -$0.46 in Q4 2025 year-over-year; TTM through Nov 2025 was -$0.3, a 700.0% decrease, with the full-year FY2025 number at -$0.3, down 700.0% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.46 for Q4 2025 at Cryo Cell International, down from $0.09 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.14 in Q2 2021 to a low of -$1.34 in Q4 2023.
  • A 5-year average of -$0.04 and a median of $0.08 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 242.86% in 2022, then tumbled 1440.0% in 2023.
  • Cryo Cell International's EPS (Weighted Average and Diluted) stood at -$0.07 in 2021, then surged by 242.86% to $0.1 in 2022, then crashed by 1440.0% to -$1.34 in 2023, then surged by 83.58% to -$0.22 in 2024, then plummeted by 109.09% to -$0.46 in 2025.
  • Per Business Quant, the three most recent readings for CCEL's EPS (Weighted Average and Diluted) are -$0.46 (Q4 2025), $0.09 (Q3 2025), and $0.04 (Q2 2025).